Epigenetic Memory of Colitis Linked to Accelerated Tumor Growth

Chronic inflammation has long been recognized as a risk factor for cancer, but the biological mechanisms connecting these processes have remained incompletely understood. A new study published in Natureprovides compelling evidence that inflammatory episodes can leave a durable epigenetic imprint on intestinal stem cells—one that persists well beyond clinical recovery and may directly promote tumor development.

Using a mouse model of colitis, investigators demonstrated that colonic stem cells retain a form of “epigenetic memory” of inflammation that endures for more than 100 days after apparent tissue recovery. Although gene expression largely returned to baseline following resolution of inflammation, persistent alterations were observed at the level of chromatin accessibility, indicating that prior inflammatory exposure was encoded in the epigenome rather than the transcriptome.

Central to this memory was increased activity of activator protein 1 (AP-1), a transcription factor complex known to regulate cellular responses to stress and injury. The study found a sustained gain in chromatin accessibility at AP-1 binding sites, reflecting a long-lived shift in how stem cells respond to environmental cues. Notably, this epigenetic signature was not uniform: a subset of stem cells exhibited particularly high AP-1 activity, suggesting heterogeneity in how inflammatory experiences are retained at the cellular level.

To track how this memory is maintained, the researchers developed a novel single-cell method—SHARE-TRACE—capable of simultaneously measuring gene expression, chromatin accessibility, and clonal lineage. This approach revealed that epigenetic memory is propagated intrinsically within stem cells and inherited across cell divisions. Certain clones retained stronger memory signatures than others, indicating that prior inflammatory exposure can create distinct subpopulations with altered biological potential.

Functionally, this memory state was associated with a gene program enriched for wound healing, cytoskeletal remodeling, and stem cell proliferation. Although these programs were transiently activated during inflammation, the underlying epigenetic priming persisted, enabling a more rapid or amplified response upon subsequent stimuli.

Crucially, the study demonstrates that this epigenetic memory has direct implications for tumorigenesis. When oncogenic mutations were introduced in mice that had recovered from colitis, tumors were significantly larger compared with those in controls, despite similar tumor numbers. Further analysis showed that early microscopic lesions were also larger, suggesting that prior inflammation enhances initial tumor outgrowth rather than tumor initiation per se.

At the molecular level, tumors arising in colitis-experienced tissue exhibited increased expression of AP-1–regulated gene programs, mirroring the epigenetic state observed in pre-neoplastic stem cells. Pharmacologic inhibition of AP-1 during tumor initiation reduced tumor size by nearly 40% in these animals, underscoring the functional importance of this pathway in mediating the pro-tumorigenic effects of inflammatory memory.

Mechanistically, the study also identified cooperation between AP-1 and forkhead box (FOX) transcription factors in stabilizing these epigenetic changes, further refining the regulatory architecture underlying memory formation. These interactions appear to enhance AP-1 binding and sustain accessibility at key genomic regions involved in repair and proliferation.

Taken together, the findings establish a mechanistic link between chronic inflammation and cancer risk, showing that inflammatory episodes can durably reprogram stem cells in ways that lower the threshold for malignant transformation. This work introduces the concept of “epigenetic field cancerization,” in which clonal populations of cells harbor long-lived, non-mutational alterations that predispose tissue to disease.

Beyond mechanistic insight, the study raises potential clinical implications. Persistent epigenetic signatures could serve as biomarkers for cancer risk in patients with chronic inflammatory conditions such as ulcerative colitis. At the same time, targeting pathways like AP-1 may offer a strategy to interrupt the progression from inflammation to malignancy—an approach that could reshape prevention efforts in high-risk populations.